64544-19-0

Basic information

• Product Name: 4-bromo-N-(2-morpholin-4-ylethyl)benzamide
• Synonyms: benzamide, 4-bromo-N-[2-(4-morpholinyl)ethyl]-
• CAS NO: 64544-19-0
• Molecular Formula: C₁₃H₁₇BrN₂O₂
• Molecular Weight: 313.1903
• Mol File: 64544-19-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 462.3°C at 760 mmHg
• Flash Point: 233.4°C
• Density: 1.379g/cm³
• Vapor Pressure: 9.95E-09mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 4-bromo-N-(2-morpholin-4-ylethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-N-(2-morpholin-4-ylethyl)benzamide(64544-19-0)
• EPA Substance Registry System: 4-bromo-N-(2-morpholin-4-ylethyl)benzamide(64544-19-0)

Safety Data

• Hazardous Substances Data: 64544-19-0(Hazardous Substances Data)

Upstream product

• 56075-37-7 1-(methylsulfonyl)-2-(4-bromophenyl)diazene 
• 78375-48-1 2-morpholinoethyl isonitrile 
• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 
• 586-75-4 4-chlorobenzoyl chloride 

Relevant articles and documents

An iodinated derivative of moclobemide as potential radioligand for brain MAO-A exploration

In vivo evaluation of MAO-A would be of great value for the diagnosis and follow-up of therapy of depression. In order to perform this exploration by SPECT, we developed an iodinated derivative of the reversible MAO-A inhibitor, moclobemide. Ro 11-9900 was synthesized and analysed by IR, NMR and HPLC. Radioiodination was carried out by nucleophilic exchange of [125I] on the brominated precursor, and yielded [125I]-Ro 11-9900 with high specific activity. In vitro experiments on rat brain homogenates showed that Ro 11-9900 had poor inhibitory activity on MAO-A, as already described for moclobemide. By contrast, in vivo biodistribution in the rat brain showed that [125I]-Ro 11-9900 accumulated in a region corresponding to the localization of-locus coeruleus known for its high density of MAO-A. Moreover, preinjection of the irreversible MAO-A inhibitor clorgyline (10 mg.kg-1) prevented accumulation of radioactivity by 40 to 60% and we found that the radioactivity in the brain corresponded exclusively to [125I]-Ro 11-9900 and not to a metabolite. [125I]-Ro 11-9900 was highly accumulated in the pineal gland, both on MAO-A and on MAO-B sites. We concluded that the unmetabolized iodinated derivative of moclobemide, Ro 11-9900, preferentially labeled MAO-A in vivo in the rat brain. This compound would therefore be a potential tracer for evaluation of MAO-A by SPECT.

PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.